The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical significance of the CGRP pathway gene expression in advanced solid tumors: A sub-analysis of MONSTAR-SCREEN-2.
 
Takao Fujisawa
Honoraria - Amelief; AstraZeneca; Merck Serono
 
Naoya Sakamoto
No Relationships to Disclose
 
Yoshiaki Nakamura
Consulting or Advisory Role - DAIICHI SANKYO Co., Ltd.; Exact Sciences; Gilead Sciences; Guardant Health Pte Ltd; Natera,Inc.; Premo Partners, Inc.; Roche Ltd./; Seagen,Inc.; Takeda
Speakers' Bureau - Becton Dickinson; CareNet,Inc.; Chugai Pharma; DAIICHI SANKYO Co., Ltd.; Eisai; Guardant Health Japan Corp.; Guardant Health Pte Ltd; Hisamitsu Pharmaceutical; Merck; Miyarisan pharmaceutical; MSD K.K; Taiho Pharmaceutical; Zeria Pharmaceutical
Research Funding - Chugai Pharma (Inst); DAIICHI SANKYO Co., Ltd. (Inst); Genomedia (Inst); Guardant Health (Inst); Guardant Health AMEA, Inc. (Inst); Roche (Inst); Seagen,Inc. (Inst); Tempus (Inst)
 
Riu Yamashita
Consulting or Advisory Role - Takeda
 
Takeshi Kuwata
Honoraria - Astellas Pharma; Bayer; Daiichi Sankyo; FALCO biosystems; MSD; Roche
Consulting or Advisory Role - Astellas Pharma; Daiichi Sankyo; Roche
Research Funding - Takeda (Inst)
 
Michiko Nagamine
Honoraria - GxD, Inc; Matsunami Glass Ind.,Ltd.; SRL Diagnostics
 
Genichiro Ishii
No Relationships to Disclose
 
Chigusa Morizane
Honoraria - AstraZeneca; Chugai Pharma; Eisai; Guardant Health; Incyte Japan; MSD K.K.; Myriad Genetics; Novartis; SERVIER; Sysmex; Taiho Pharmaceutical
Consulting or Advisory Role - Abbvie; AstraZeneca; BioNTech SE; Boehringer Ingelheim; Merck; MSD K.K.; Pfizer; Revolution Medicines; SERVIER; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo RD Novare (Inst); Eisai (Inst); EPS Corporation (Inst); Hitachi (Inst); LabCorp (Inst); ONO PHARMACEUTICAL (Inst); Taiho Pharmaceutical (Inst)
 
Norio Nonomura
Honoraria - Astellas Pharma; AstraZeneca; Asuka Seiyaku; Bayer; Bristol-Myers Squibb; Chugai Pharma; Eisai; Janssen; Kissei Pharmaceutical; Kyorin; MSD; Nippon Shinyaku; Ono Pharmaceutical; Pfizer; Takeda
Research Funding - Nippon Shinyaku (Inst)
 
Hiroji Iwata
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Hakko Kirin; Lilly Japan; MSD; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly Japan; MSD; Novartis; Pfizer; Sanofi
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); MSD (Inst); Nihonkayaku (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst)
 
Susumu Okano
Speakers' Bureau - Bristol-Myers Squibb Japan; Meiji Seika Kaisha; Merck Serono; MSD; Ono Pharmaceutical
 
Hidemichi Watari
Honoraria - AstraZeneca; Takeda
Research Funding - Chugai Pharma; Hokkaido Cancer Society; Hokkaido Welfare Federation of Agricultural Corporatives; Kaken Pharmaceutical; Mochida Pharmaceutical Co. Ltd.; Taiho Pharmaceutical
Other Relationship - T-PEC
 
Kenjiro Namikawa
Honoraria - Bristol-Myers Squibb; MSD; Novartis; Ono Pharmaceutical
Consulting or Advisory Role - MSD; Novartis
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Novartis (Inst); Ono Pharmaceutical (Inst)
 
Tadayoshi Hashimoto
Honoraria - Cytogen; Takata Pharmaceutical
 
Taro Shibuki
No Relationships to Disclose
 
Mitsuho Imai
Patents, Royalties, Other Intellectual Property - 1. ?NCC's Reference: #2023-03 Filing number (Filing date): US 63/468,666 (2023.05.24) Title: METHOD OF USING AN ARTIFICIAL INTELLIGENCE-POWERED WHOLE SLIDE IMAGE (WSI) ANALYSIS TO PREDICT TUMOR RESPONSE TO SUBSEQUENT IMMUNE CHECKPOINT INHIBITOR TREATMEN
 
Hideaki Bando
Honoraria - Chugai Pharma; Ono Pharmaceutical; Taiho Pharmaceutical
 
Milan Radovich
Employment - Caris Life Sciences
Leadership - Caris Life Sciences
Patents, Royalties, Other Intellectual Property - Patents developed at Caris Life Sciences (Inst)
Travel, Accommodations, Expenses - Caris Life Sciences
 
Hidemi Takagi
No Relationships to Disclose
 
Takayuki Yoshino
Honoraria - Chugai Pharma; Merck; MSD K.K.; Takeda
Consulting or Advisory Role - Sumitomo Corp.
Research Funding - Amgen (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); DAIICHI SANKYO COMPANY, LIMITED (Inst); Eisai (Inst); FALCO biosystems Ltd. (Inst); Medical & Biological Laboratories Co., Ltd. (Inst); Merus (Inst); Molecular Health (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)